Evidence in Favor of Braak Staging of Parkinson's Disease

被引:102
|
作者
Dickson, Dennis W. [1 ]
Uchikado, Hirotake
Fujishiro, Hiroshige
Tsuboi, Yoshio
机构
[1] Mayo Clin, Neuropathol Lab, Dept Neurosci, Jacksonville, FL 32224 USA
关键词
alpha-synuclein; Lewy bodies; Parkinson's disease staging; neuropathology; ALPHA-SYNUCLEIN PATHOLOGY; AUTONOMIC NERVOUS-SYSTEM; LEWY BODY DISEASE; ALZHEIMERS-DISEASE; BRAIN PATHOLOGY; BODIES; DEMENTIA; INCLUSIONS; DIAGNOSIS; AMYGDALA;
D O I
10.1002/mds.22637
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recently, Braak and coworkers proposed a pathologic staging scheme for Parkinson disease (PD). In this staging, scheme substantia nigra pathology occurs at midstage disease, while involvement of anterior olfactory nucleus, medulla, and pontine tegmentum occur earlier. In the last stages. Lewy bodies (LBs) involve cortical areas. The general principles of the proposed staging system have been confirmed in several studies of PD, but it does not appear to fit with all LB disorders. We studied the density and distribution of LBs with alpha-synuclein immunohistochemistry in normal elderly with incidental LBs (N = 12); progressive supranuclear palsy (PSP) with incidental LBs (N = 18); Lewy body disease (LBD) with minimal or no Alzheimer type pathology (N = 52); LBD with concomitant Alzheimer disease (AD) (N 84); and cases of AD with amygdala predominant LBs (N = 64). The proportion of cases that fit the PD staging scheme was 67% for incidental LBs; 86% for PSP with LBs; 86% for pure LBD; and 84% for LBD with AD; but only 6% for AD with amygdala predominant LBs. The PD staging scheme is valid, except in the setting of advanced AD. In this situation, LBs may be unrelated to PD and more likely related to factors inherent to AD and the selective vulnerability of the amygdala to both Alzheimer and alpha-synuclein pathologies. (C) 2010 Movement Disorder Society
引用
收藏
页码:S78 / S82
页数:5
相关论文
共 50 条
  • [1] A critical review of the Braak staging scheme for Parkinson's disease
    Dickson, D. W.
    Uchikado, H.
    Klos, K. J.
    Josephs, K. A.
    Boeve, B. F.
    Ahlskog, J.
    [J]. MOVEMENT DISORDERS, 2006, 21 : S559 - S559
  • [2] Is Braak staging valid for all types of Parkinson’s disease?
    Kurt A. Jellinger
    [J]. Journal of Neural Transmission, 2019, 126 : 423 - 431
  • [3] A Critical Evaluation of the Braak Staging Scheme for Parkinson's Disease
    Burke, Robert E.
    Dauer, William T.
    Vonsattel, Jean Paul G.
    [J]. ANNALS OF NEUROLOGY, 2008, 64 (05) : 485 - 491
  • [4] Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease
    Schindlbeck, Katharina A.
    Eidelberg, David
    [J]. LANCET NEUROLOGY, 2019, 18 (08): : 713 - 714
  • [5] Critical Evaluation of the Braak Staging Scheme for Parkinson's Disease
    Jellinger, Kurt A.
    [J]. ANNALS OF NEUROLOGY, 2010, 67 (04) : 550 - 550
  • [6] Is Braak staging valid for all types of Parkinson's disease?
    Jellinger, Kurt A.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (04) : 423 - 431
  • [7] Evaluation of Braak staging in at-risk individuals for Parkinson's disease
    Basu, P.
    Govindappa, S. T.
    Subbukrishna, D. K.
    Muthane, U.
    Muthane, U.
    [J]. MOVEMENT DISORDERS, 2012, 27 : S491 - S492
  • [8] Brain Stem Pathology in Parkinson's Disease: An Evaluation of the Braak Staging Model
    Kingsbury, Ann E.
    Bandopadhyay, Rina
    Silveira-Moriyama, Laura
    Ayling, Hilary
    Kallis, Constantinos
    Sterlacci, William
    Maeir, Hans
    Poewe, Werner
    Lees, Andrew J.
    [J]. MOVEMENT DISORDERS, 2010, 25 (15) : 2508 - 2515
  • [9] Evaluation of the Braak Staging Scheme for Parkinson's disease: Introduction to a Panel Presentation
    Burke, Robert E.
    [J]. MOVEMENT DISORDERS, 2010, 25 (03) : S76 - S77
  • [10] Parkinson's Disease: "Braak" to the future
    Blesa, Javier
    [J]. MOVEMENT DISORDERS, 2013, 28 (09) : 1209 - 1209